Core Viewpoint - The December Central Political Bureau meeting emphasizes the importance of maintaining a stable yet progressive approach to economic work in 2026, focusing on expanding domestic demand and optimizing supply to enhance resource allocation efficiency [1][6][21]. Economic Goals and Policy Framework - The meeting highlights the need to continue expanding domestic demand and optimizing supply, aiming for both qualitative and quantitative growth in the economy during the "14th Five-Year Plan" period [1][21]. - The overall policy framework for 2026 will maintain a proactive stance, with a focus on enhancing the quality and effectiveness of development, alongside a more active fiscal policy and moderately loose monetary policy [2][8][22]. Industry Policy Deployment - The meeting outlines a clear path for industry planning in 2026, prioritizing domestic demand and innovation, which will benefit sectors such as consumer goods, AI, digital economy, and new energy [3][10][24]. - Emphasis is placed on reform, opening up, and coordinated development to enhance high-quality growth, benefiting state-owned enterprises and infrastructure-related sectors [3][10][24]. Implications for A-Share Investment - The meeting provides initial guidance for economic work in 2026, focusing on domestic demand, innovation, and reform, which is expected to stabilize market expectations and boost confidence in the A-share market [4][17][26]. - Upcoming central economic work meetings are anticipated to detail specific fiscal, monetary, and industrial measures, further activating market vitality [4][17][26]. Investment Focus Areas - The current policy window indicates a clearer structural focus for 2026, with attention on new productive forces such as AI, renewable energy, and quantum technology, alongside recovery paths for manufacturing and resource sectors [12][26]. - The consumer sector is expected to see a favorable investment environment due to policies aimed at boosting domestic demand, while the trend of companies expanding overseas will enhance profit potential [12][26].

Investment Rating - The industry investment rating is "Outperform the Market" with an expectation of over 10% relative increase in the industry index compared to the market in the next six months [5][10]. Core Insights - The new medical insurance drug list has been released, adding 50 first-class innovative drugs. A total of 114 new drugs were added, with a success rate of 88%, higher than last year's 76%. The total number of drugs in the list has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines. This new list will be implemented starting January 1, 2026 [3]. - The first commercial health insurance innovative drug list has been published, including 19 drugs from 18 pharmaceutical companies, covering treatments for cancer, rare diseases, and Alzheimer's disease. These drugs are not included in the medical insurance fund payment scope, promoting the development of a multi-tiered medical security system and increasing accessibility to high-value innovative drugs [4]. - The collaboration between the new medical insurance drug list and the commercial health insurance innovative drug list aims to create a new payment structure for innovative drugs, addressing the affordability issue for patients and providing a sustainable return mechanism for pharmaceutical companies, thus driving high-quality development in China's innovative drug industry [4]. Summary by Sections - **New Medical Insurance Drug List**: 50 first-class innovative drugs added, total drugs increased to 3,253, with a record number of 69 innovative drugs approved for market entry this year [3]. - **Commercial Health Insurance Drug List**: 19 innovative drugs included, enhancing accessibility and complementing the basic medical insurance system [4]. - **Policy Impact**: The synergy between the two lists is expected to accelerate the development of China's innovative drug research and create a robust engine for high-quality growth in the industry [4].

Core Insights - The recent adjustment of the National Medical Insurance Directory for 2025 has significantly benefited XuanZhu Biotech, marking a pivotal moment for its innovative drugs [1][2] - The inclusion of the CDK4/6 inhibitor Palbociclib and the renewal of the proton pump inhibitor Anaprazole in the insurance directory are crucial for the commercialization phase of these products [2][4] Product Developments - Palbociclib is the only approved single-agent treatment for HR+/HER2- breast cancer in China, with a projected market growth from 3 billion yuan in 2024 to 13 billion yuan by 2032, reflecting a compound annual growth rate of 20.2% [5][8] - Anaprazole, as the first self-developed PPI in China, has shown steady revenue growth, achieving approximately 30.1 million yuan and 17.9 million yuan in revenue for the fiscal years ending December 31, 2024, and June 30, 2025, respectively [10] Market Positioning - The successful inclusion of these drugs in the insurance directory enhances patient accessibility and aligns with the industry's trend towards addressing clinical needs and achieving scale [4][10] - XuanZhu Biotech's strategic focus on differentiated innovation and expanding its product pipeline positions it well against the backdrop of increasing competition in the innovative drug sector [12][13] Financial Performance - The company has demonstrated a robust capital structure, with over 20% of its shares held by external investment institutions, indicating strong recognition of its R&D capabilities [2] - The transition from a biotech phase reliant on financing to a biopharma phase capable of generating cash flow is evident as the company’s R&D expenditures decrease while revenue increases [22] Strategic Collaborations - XuanZhu Biotech's collaboration with Akamis Bio to introduce the injectable oncolytic virus therapy NG-350A highlights its commitment to expanding its innovative pipeline and enhancing its market presence [16] - The company is also advancing several first-in-class products, such as the HER2 dual-targeting ADC KM501 and the CD80 fusion protein KM602, which are currently in clinical trials [15] Market Trends - The innovative drug sector is experiencing a shift from a focus on pipeline scarcity to a demand for tangible commercialization results, with investors prioritizing companies that can efficiently convert R&D into marketable products [18][19] - XuanZhu Biotech's established sales teams and distribution networks in the oncology and digestive disease sectors provide a solid foundation for rapid product uptake [20] Long-term Outlook - The combination of immediate revenue growth from newly approved products and a long-term strategy focused on differentiated pipeline development positions XuanZhu Biotech favorably for future valuation increases [25] - The company's ability to balance short-term performance with long-term growth potential is expected to attract investor interest in the evolving landscape of the innovative drug market [23][24]

Group 1 - The market is currently experiencing a period of low trading volume and volatility as investors await guidance from the Central Economic Work Conference, with a focus on domestic demand policies [1][13] - The adjustment of risk factors for insurance companies is expected to enhance their capital allocation capabilities, allowing for increased investment in core assets, dividend stocks, and technology innovation sectors [2][3][18] - The financial regulatory authority has proposed to moderately expand the capital space and leverage limits for high-quality brokerage firms, which is seen as a positive signal for the capital market and non-bank sectors [1][2] Group 2 - The upcoming Federal Reserve meeting is anticipated to provide insights into monetary policy, with market expectations leaning towards a potential interest rate cut in December, despite inflationary pressures suggesting a hawkish stance [5][11] - The divergence in monetary policies between the US and Japan may raise liquidity concerns, as Japan's government has announced a significant economic stimulus plan [11][12] - The overall economic environment in China remains weak, with manufacturing PMI and real estate sales showing continued decline, prompting a cautious approach to investment strategies [13][16] Group 3 - The insurance sector's risk factor adjustments are designed to optimize solvency regulation and enhance long-term investment capabilities, supporting the technology and foreign trade industries [2][3][18] - Financial institutions, particularly those with stable earnings and high dividend yields, are recommended as safe investment options during periods of defensive demand [15][18] - The market is advised to focus on sectors with clear growth trends, such as AI-related industries, renewable energy, and international pharmaceuticals, as liquidity conditions improve [15][18]

Core Viewpoint - The Hong Kong stock market is stabilizing and returning to a fluctuating upward trend, with the technology sector expected to further consolidate and recover as market sentiment improves [1] Group 1: Market Overview - The Hong Kong Technology ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), which includes core assets in sectors such as internet, semiconductors, innovative pharmaceuticals, and new energy vehicles, reflecting the diversified characteristics of the technology industry [1] - The Hong Kong Stock Connect Technology Index has a higher allocation in new energy vehicles, innovative pharmaceuticals, and semiconductors compared to the Hang Seng Technology Index [1] Group 2: Performance Metrics - From the base date at the end of 2014 to the end of October 2025, the cumulative return of the Hong Kong Stock Connect Technology Index is 256.46%, significantly outperforming the Hang Seng Technology Index, which has a return of 96.94%, by nearly 160% [1] - The Hong Kong Stock Connect Technology Index has consistently outperformed other indices, including the Hang Seng Technology Index, the Shanghai-Hong Kong-Shenzhen Internet Index, the Hang Seng Internet Technology Index, and the Hang Seng Healthcare Index [1]

商业航天板块多股连板，航天科技、西部材料等2连板。一图速览今日连板股>> 12月8日，Wind数据显示，A股市场共计78只个股涨停。其中创新药板块瑞康医药收获4连板，人形机器 人概念股骏亚科技4连板；商业航天板块多股连板，航天科技、西部材料等2连板。一图速览今日连板股 >> | | 连板服投 12.8 一板 | | | --- | --- | --- | | 股票名称 | 连板天数 | 所属概念 | | 安记食品 | 5 | 调味品 | | 瑞康医药 | 4 | 创新药 | | 龙洲股份 | 4 | 机器人 | | 骏亚科技 | 4 | 人形机器人 | | 双星新材 | 3 | 基础化工 | | 舒华体育 | 3 | 体育产业 | | 冰轮环境 | 2 | 液冷+核聚变 | | 航天科技 | 2 | 商业航天+卫星导航 | | 厦门港务 | 2 | 港口物流 | | *ST钢昌 | 2 | 商业航天 | | 南矿集团 | 2 | 黄金 | | 西部材料 | 2 | 商业航天+可控核聚变 | | 精艺股份 | 2 | 铜 | | 顺灏股份 | 2 | 商业航天 | | 闽发铝业 | 2 | 铝 | | 福建金森 ...

对于2026年的跨年行情，华夏、嘉实、中信保诚、鹏华、永赢、中信建投、德邦、博时、东吴、银华、 中泰证券资管、国寿安保、兴全等十几家知名公募旗下的明星基金经理给予了本刊回复 。 2025年进入最后一月，大牛市中荡气回肠的一年即将收官。岁末回眸，最值得铭记的瞬间就是10月底， 市场成功站上4000点的十年新高。这不仅是一次整数点位的突破，更是市场信心与估值体系实现根本性 修复的标志。同样值得铭记的是，中国产业升级与科技创新的时代缩影，已经在2025年映射到股市的方 方面面。 年初，以DeepSeek为代表的大模型公司在算法与多模态推理上实现里程碑式突破，点燃了整个人工智 能产业链的投资热情，推动算力、数据、应用等环节个股股价迭创新高。与此同时，一批具备全球竞争 力的高端制造业龙头强势崛起，在出海拓展与技术领先上取得实质性进展，其中部分龙头市值超越部分 传统蓝筹，成为中国经济转型升级在资本市场上的生动印证。久违的赚钱效应回归，也让股票投资者和 公募基金投资者赚到了真金白银。 对于2026年的资本市场，由此他们更多了一份期待。但经历过今年热点的快速轮动后，他们对于2026年 的市场会有哪些变化，尤其是投向哪些赛道还 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

Market Performance - The Shanghai Composite Index rose by 0.54%, the Shenzhen Component Index increased by 1.39%, the ChiNext Index surged by 2.6%, and the North Star 50 gained 1.27% [1] - The total market turnover reached 2.05 trillion yuan, an increase of 312.6 billion yuan compared to the previous day, marking the first time in 16 trading days that turnover surpassed 2 trillion yuan [1] Sector Highlights - The computing hardware sector showed strong performance, particularly in the CPO direction, leading the market [1] - Active sectors included lithium mining, cross-strait integration, photolithography machines, superhard materials, consumer electronics, and commercial aerospace [1] - Conversely, resource stocks such as coal and oil & gas experienced weakness [1] ETF Performance - The AI hardware sector saw significant gains, with the Fortune Fund Communication Equipment ETF, the Huashan Entrepreneurial AI ETF, and the Dazhong Entrepreneurial AI ETF rising by 5.65%, 5.62%, and 5.56% respectively [1] - The storage chip sector also strengthened, with the Huatai-PineBridge Korea Semiconductor ETF increasing by 4.47% [1] - Two Brazilian ETFs declined by 6.3% [1] - Pop Mart experienced a significant drop, with the Hang Seng Consumer ETF and the Hong Kong Stock Connect Consumer ETF falling by 1.91% and 1.88% respectively [1] - The Hong Kong innovative drug sector weakened, with the Fortune Hong Kong Stock Connect Medical ETF and the Industrial and Commercial Bank of China Hong Kong Stock Connect Innovative Drug ETF both declining by 1.5% [1] - The coal sector adjusted, with the coal ETF dropping by 1.5% [1]

Core Viewpoint - The pharmaceutical and biotechnology market currently lacks a clear main theme, but the release of the first "Medical Insurance + Commercial Insurance Dual Directory" by the National Healthcare Security Administration on December 7 may boost investment enthusiasm for innovative drugs [1] Market Performance - Last week, the pharmaceutical and biotechnology sector had a return of -0.74%, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices [2] - The pharmaceutical commercial sub-sector had the highest weekly return at 5.19%, outperforming the CSI 300 by 3.91%, while the medical services sub-sector ranked sixth with a return of -1.37%, underperforming the CSI 300 by 2.65% [2] Innovative Drugs - Companies recommended for investment in innovative drugs include: - Innovent Biologics - 3SBio - Hengrui Medicine - Kelun-Biotech - Baillie Gifford - Rongchang Biologics - Yimeng Biologics - Huyou Pharmaceutical - King’s Ray Biotech - Valiant Biotech - Lee's Pharmaceutical [2] CXO and Life Sciences Upstream Industry Chain - Recommended global CXO leaders include: - WuXi AppTec - WuXi Biologics - WuXi AppTec's subsidiary - Kanglong Chemical - Kailai Ying [3] - Recommended domestic clinical CRO leaders include: - Tigermed - Proprius - Nossg - Sunshine Nuohe [3] - Recommended resource-type CXOs include: - Zhaoyan New Drug - Yinos - Medicy - Baiaosaitu - Yaokang Biotech [3] - Recommended companies in the life sciences upstream industry chain include: - Baipusais - Haoyuan Pharmaceutical - Bid Pharmaceutical - Nami Technology - Aopumai - Haier Biomedical - Aladdin - Titan Technology [3] Companies with Improved Operations and High Dividends - Companies recommended for attention include: - Baiyunshan - Sinopharm [4] High-end Medical Equipment - Recommended companies benefiting from overseas pharmaceutical investments include: - Sensong International - Dongfulong - Chutian Technology [4] - Companies expected to see business growth from hospital procurement recovery include: - United Imaging - Kaili Medical - Xinhua Medical - Mindray Medical - Aohua Endoscopy - Mountain Outside Mountain [4] - Companies with domestic demand-driven medical device recovery include: - Yiyue Medical - Kefu Medical - Sanofi Biotech [4] - Companies with restored overseas orders include: - Meihua Medical - Haitai New Light - Ruimaite [4] - Companies with increasing market penetration in high-end medical consumables include: - Xinmai Medical - Micron Medical - Weigao - Micron Brain Science - Aikang Medical - Chunli Medical [4]